Prokaryotics Licenses Innovative Antibiotic Potentiator
Prokaryotics Inc., a leader in anti-infective drug development, has entered a pivotal licensing agreement with Northern Antibiotics. This collaboration focuses on the Gram-negative antibiotic potentiator, NAB741, previously known as SPR741. This unique compound is a non-bioactive polymyxin, created by a renowned team under Dr. Martti Vaara, and is designed to enhance antibiotic effectiveness against challenging Gram-negative bacteria.
The Significance of NAB741
NAB741 works by increasing the permeability of the outer membrane of Gram-negative bacteria, effectively making these pathogens more vulnerable to existing antibiotics. The recent Phase 1 clinical trials have successfully demonstrated its safety and tolerability, which is a significant milestone in the journey of NAB741 towards market readiness. Prokaryotics aims to leverage these promising results in their ongoing development efforts.
Expert Insights on the Collaboration
According to Terry Roemer, Ph.D., Chairman and Chief Scientific Officer at Prokaryotics, this agreement represents a substantial addition to their lineup of innovative antibiotic solutions. He highlighted that NAB741 enhances the efficacy of current antibiotics and can counteract the growing concern of antibiotic resistance. This approach fosters the potential development of combination therapies that can significantly improve outcomes for patients battling resistant bacterial infections.
Complementing the Antibiotic Landscape
The collaboration highlights NAB741's role not just as a standalone agent but in conjunction with other antibiotics produced by Prokaryotics. This synergy aligns with the company's mission to address life-threatening infections caused by antimicrobial-resistant organisms. Timo Vaara of Northern Antibiotics emphasized the importance of collaborative efforts in ensuring the development of unique and effective antibiotic treatments.
About Prokaryotics, Inc.
Founded on the experience and resources from Merck & Co., Prokaryotics, Inc. specializes in creating cutting-edge solutions for antimicrobial resistance. Their extensive knowledge of bacterial physiology and medicinal chemistry enables the discovery of novel antibiotic classes that specifically address the challenges posed by microbial cell wall structures.
Contact Information for Inquiries
For further inquiries about Prokaryotics' innovative projects and partnerships, you can reach out to Holly Sutterlin at 908 737-1922 ext. 124. The company is dedicated to advancing treatments that significantly impact public health, specifically targeting infections that current antibiotics fail to manage. Their commitment to scientific excellence and collaboration continues to drive the fight against resistant bacteria.
Frequently Asked Questions
What is the focus of Prokaryotics Inc.?
Prokaryotics Inc. focuses on the discovery and development of novel anti-infective drugs, particularly targeting resistant bacterial infections.
What is NAB741?
NAB741 is a Gram-negative antibiotic potentiator that increases the permeability of bacterial membranes, enhancing the efficacy of existing antibiotics.
Who developed NAB741?
NAB741 was developed by Dr. Martti Vaara and his team at Northern Antibiotics.
What are the benefits of the licensing agreement?
The agreement allows Prokaryotics to develop and commercialize NAB741, expanding their portfolio of potential treatments for antibiotic-resistant infections.
How does NAB741 work?
NAB741 works by allowing other antibiotics to penetrate the outer membrane of Gram-negative bacteria, making them more effective against these pathogens.
